The DOI matches its Crossref record; 298 of the 298 references it cites were found in a registry or an index.
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Open accessAbstract
During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this “silent” stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This could explain why part of the risk factors for cardiovascular disease are in common with AD, including hypertension, dyslipidemia, diabetes, obesity, dietary factors, smoking, and physical activity (Figure 1B).”
From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Thus, lifestyle is also an important risk factor, where intellectual, physical, and social activities, as well as diet, may help to prevent AD [1,22,100,101,102,103].”
From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“Thus, the disease is now regarded as a continuum rather than three distinct clinically defined entities [15].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“While differences remain, IWG 2016 and the NIA research framework are aligned on the key issue that the combination of an abnormal Aβ and tau biomarker constitutes AD regardless of cognitive symptoms, and thus AD is a biologically defined entity throughout its continuum.”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [15]
In the citing paper
“Furthermore, drug development research for AD has become more complicated as preclinical and prodromal AD populations are potentially included in current trials, as well as traditionally included populations of all the clinical stages of AD dementia.38”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [38]
In the citing paper
“Although the use of clinical trial simulators is not frequent in recent research,38”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [38]
In the citing paper
“This asymptomatic phase of AD (AsymAD) is currently considered a preclinical stage of the disease [27, 28].”
From Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease (2018) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“From the tau protein perspective, one study showed that alterations in CSF levels of p-tau may precede those of Ab [57], which correlates with postmortem evidence showing the presence of neurofibrillary tangles in the entorhinal cortex and in hippocampal-related structures [58,59] as the first neuropathologic event in…”
ResultCorder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationBiomarkers and surrogate endpoints: Preferred definitions and conceptual framework
Biomarkers Definitions Working Group (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,771
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Exercise training increases size of hippocampus and improves memory
Erickson, K. I., Voss, M. W., Prakash, R. S., Basak, C., Szabo, A., Chaddock, L., Kim, J. S., Heo, S., Alves, H., White, S. M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015950108 · Cited by 4,855
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Self-citationMeta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Self-citationClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,003
The role of astrocyte‐mediated plasticity in neural circuit development and function
Perez-Catalan, N. A., Doe, C. Q., & Ackerman, S. D. (2021) · Neural Development · doi:10.1186/s13064-020-00151-9 · Cited by 146
Challenges in the practical implementation of blood biomarkers for Alzheimer’s disease
Schöll, M., Verberk, I. M. W., del Campo, M., Delaby, C., Therriault, J., Chong, J. R., Palmqvist, S., & Alcolea, D. A. (2024) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2024.07.013 · Cited by 150
Tao, L., Liu, Q., Zhang, F., Fu, Y., Zhu, X. D., Weng, X., Han, H., Huang, Y., Suo, Y., Chen, L., et al. (2021) · Light Science & Applications · doi:10.1038/s41377-021-00617-3 · Cited by 133
López‐Sanz, D., Bruña, R., Garcés, P., Martín-Buro, M. C., Walter, S., Delgado‐Losada, M. L., Montenegro, M., López-Higes, R., Marcos, A., & Maestú, F. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00109 · Cited by 129
Opwonya, J., Doan, D. N. T., Kim, S. G., Kim, J. I., Ku, B. U., Kim, S., Park, S., & Kim, J. U. (2021) · Neuropsychology Review · doi:10.1007/s11065-021-09495-3 · Cited by 156
When Does Alzheimer′s Disease Really Start? The Role of Biomarkers
Lloret, A., Esteve, D., Lloret, M.-A., Cervera-Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225536 · Cited by 131
Leuzy, A., Chiotis, K., Hasselbalch, S. G., Rinne, J. O., de Mendonça, A., Otto, M., Lleó, A., Castelo-Branco, M. S., Santana, I. J., Johansson, J. J., et al. (2016) · Brain · doi:10.1093/brain/aww160 · Cited by 135
Self-citationPET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases
Cai, Z., Li, S., Matuskey, D., Nabulsi, N., & Huang, Y. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.07.038 · Cited by 131
Gatchel, J. R., Rabin, J. S., Buckley, R. F., Locascio, J. J., Quiroz, Y. T., Yang, H., Vannini, P., Amariglio, R. E., Rentz, D. M., Properzi, M. J., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.8964 · Cited by 137
Self-citationEarly Detection of Alzheimer's Disease with Blood Plasma Proteins Using Support Vector Machines
Eke, C. S., Jammeh, E., Li, X., Carroll, C., Pearson, S., & Ifeachor, E. (2020) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2020.2984355 · Cited by 136
APOE-amyloid interaction: Therapeutic targets
Wisniewski, T., & Drummond, E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104784 · Cited by 131
Healthy Aging and Dementia: Two Roads Diverging in Midlife?
Irwin, K. E., Sexton, C. E., Daniel, T., LAWLOR, B. A., & Naçi, L. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00275 · Cited by 132
The human olfactory system in two proteinopathies: Alzheimer’s and Parkinson’s diseases
Úbeda‐Bañón, I., Saiz‐Sánchez, D., Flores‐Cuadrado, A., Corroto, E. R., González-Rodríguez, M., Villar‐Conde, S., Astillero‐Lopez, V., Cabello, J. P., Gallardo‐Alcañiz, M. J., Vaamonde‐Gamo, J., et al. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00200-7 · Cited by 131
Infectious agents and Alzheimer's disease
Piekut, T., Hurła, M., Banaszek, N., Szejn, P., Dorszewska, J., Kozubski, W., & Prendecki, M. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2102073 · Cited by 123
Kumar, S., Oh, I. Y., Schindler, S. E., Lai, A. M., Payne, P., & Gupta, A. (2021) · JAMIA Open · doi:10.1093/jamiaopen/ooab052 · Cited by 125
Prevalence of preclinical Alzheimer disease
Kern, S., Zetterberg, H., Kern, J., Zettergren, A., Wærn, M., Höglund, K., Andréasson, U., Wetterberg, H., Börjesson‐Hanson, A., Blennow, K., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005476 · Cited by 123
Self-citationNagaraj, S., Zoltowska, K. M., Laskowska-Kaszub, K., & Wojda, U. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.10.008 · Cited by 123
Mitolo, M., Tonon, C., Morgia, C. L., Testa, C. M., Carelli, V., & Lodi, R. (2018) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000494921 · Cited by 126
Neurobiological Highlights of Cognitive Impairment in Psychiatric Disorders
Morozova, A. Y., Zorkina, Y., Abramova, O. V., Pavlova, O., Ka, P., Soloveva, K., Volkova, M., Alekseeva, P. A., Andryshchenko, A., Kostyuk, G. P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031217 · Cited by 132
Franks, K. H., Bransby, L., Saling, M. M., & Pase, M. P. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-210094 · Cited by 119
Feng, F., Wang, P., Zhao, K., Zhou, B., Yao, H., Meng, Q., Wang, L., Zhang, Z., Ding, Y., Wang, L., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00290 · Cited by 122
Chou, Y., Sundman, M., That, V. T., Green, J., & Trapani, C. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101660 · Cited by 133
PRECISION MEDICINE - THE GOLDEN GATE FOR DETECTION, TREATMENT AND PREVENTION OF ALZHEIMER’S DISEASE
Hampel, H. J., O’Bryant, S. E., Castrillo, J. I., Ritchie, C. W., Rojkova, K., Broich, K., Benda, N., Nisticò, R., Frank, R., Dubois, B., et al. (2016) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2016.112 · Cited by 117
Self-citationWolfsgruber, S., Polcher, A., Koppara, A., Kleineidam, L., Frölich, L., Peters, O., Hüll, M., Rüther, E., Wiltfang, J., Maier, W., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161252 · Cited by 114
Alzheimer's disease including focal presentations
Villain, N., & Dubois, B. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1681041 · Cited by 113
Self-citationFDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis
Botha, H., Mantyh, W. G., Murray, M. E., Knopman, D. S., Przybelski, S. A., Wiste, H. J., Graff‐Radford, J., Josephs, K. A., Schwarz, C. G., Kremers, W. K., et al. (2018) · Brain · doi:10.1093/brain/awy049 · Cited by 112
Self-citationStaging of Alzheimer’s disease: past, present, and future perspectives
Therriault, J., Zimmer, E. R., Benedet, A. L., Pascoal, T. A., Gauthier, S. G., & Rosa‐Neto, P. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.05.008 · Cited by 123
Self-citationAβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110
Self-citationBaldacci, F., Lista, S., Cavedo, E., Bonuccelli, U., & Hampel, H. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1304217 · Cited by 113
Self-citationIncreased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later
Nägga, K., Gustavsson, A., Stomrud, E., Lindqvist, D., van Westen, D., Blennow, K., Zetterberg, H., Melander, O., & Hansson, O. (2017) · Neurology · doi:10.1212/wnl.0000000000004749 · Cited by 118
Self-citationPrecision pharmacology for Alzheimer’s disease
Hampel, H. J., Vergallo, A., Aguilar, L. F., Benda, N., Broich, K., Cuello, A. C., Cummings, J. L., Dubois, B., Federoff, H. J., Fiandaca, M. S., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.014 · Cited by 114
Self-citationBurhanullah, M. H., Tschanz, J. T., Peters, M. E., Leoutsakos, J., Matyi, J., Lyketsos, C. G., Nowrangi, M. A., & Rosenberg, P. B. (2019) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.03.023 · Cited by 107
Yeung, C. H. C., & Schooling, C. M. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyaa241 · Cited by 112
Open science datasets from PREVENT-AD, a longitudinal cohort of pre-symptomatic Alzheimer’s disease
Tremblay‐Mercier, J., Madjar, C., Das, S., Binette, A. P., Dyke, S. O. M., Etienne, P. E., Lafaille‐Magnan, M., Remz, J., Bellec, P., Collins, D. L., et al. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102733 · Cited by 115
Self-citationAlzheimer's disease in Down syndrome: an overlooked population for prevention trials
Strydom, A., Coppus, A., Blesa, R., Danek, A., Fortea, J., Hardy, J., Levin, J., Nuebling, G., Rebillat, A., Ritchie, C., et al. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.10.006 · Cited by 110
Detectable Neuropsychological Differences in Early Preclinical Alzheimer’s Disease: A Meta-Analysis
Han, S. D., Nguyen, C. P., Stricker, N. H., & Nation, D. A. (2017) · Neuropsychology Review · doi:10.1007/s11065-017-9345-5 · Cited by 121
Arterial stiffness, cognitive impairment and dementia: confounding factor or real risk?
Iulita, M. F., de la Colina, A. N., & Girouard, H. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14235 · Cited by 109
Landeiro, F., Mughal, S., Walsh, K., Nye, E., Morton, J., Williams, H. M., Ghinai, I., Castro, Y., Leal, J., Roberts, N. W., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00723-1 · Cited by 119
A novel tau‐based rhesus monkey model of Alzheimer's pathogenesis
Beckman, D., Chakrabarty, P., Ott, S. P., Dao, A., Zhou, E., Janssen, W. G. M., Donis‐Cox, K., Muller, S., Kordower, J. H., & Morrison, J. H. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12318 · Cited by 112
Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease
Cohen, A. D., Landau, S. M., Snitz, B. E., Klunk, W. E., Blennow, K., & Zetterberg, H. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.12.004 · Cited by 112
Self-citationLi, X., Wang, X., Su, L., Hu, X., & Han, Y. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028188 · Cited by 105
Redox proteomics and amyloid β-peptide: Insights into Alzheimer disease
Butterfield, D. A., & Boyd‐Kimball, D. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14589 · Cited by 105
Cosín‐Tomás, M., Senserrich, J., Arumí-Planas, M., Alquézar, C., Pallàs, M., Martín‐Requero, Á., Sunol, C. E., Kaliman, P., & Sanfeliu, C. (2019) · Nutrients · doi:10.3390/nu11081764 · Cited by 108
Uzuegbunam, B. C., Librizzi, D., & Yousefi, B. H. (2020) · Molecules · doi:10.3390/molecules25040977 · Cited by 107
Mullane, K., & Williams, M. J. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113945 · Cited by 109
European Prevention of Alzheimer’s Dementia Longitudinal Cohort Study (EPAD LCS): study protocol
Solomon, A., Kivipelto, M., Molinuevo, J. L., Tom, B. D. M., & Ritchie, C. W. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-021017 · Cited by 105
Self-citationRao, R. V., Subramaniam, K. G., Gregory, J., Bredesen, A. L., Coward, C., Okada, S., Kelly, L., & Bredesen, D. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021659 · Cited by 109
Alzheimer's disease pathophysiology in the Retina
Gaire, B. P., Koronyo, Y., Fuchs, D.-T. S., Shi, H., Rentsendorj, A., Danziger, R., Vit, J., Mirzaei, N., Doustar, J., Sheyn, J., et al. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101273 · Cited by 107
Self-citationGarcez, M. L., Mina, F., Bellettini-Santos, T., Carneiro, F. G., Luz, A. P., Schiavo, G. L., Andrighetti, M. S., Scheid, M. G., Bolfe, R. P., & Budni, J. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.03.010 · Cited by 102
Silverberg, N. B., Elliott, C. L., Ryan, L. M., Masliah, E., & Hodes, R. J. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.03.004 · Cited by 112
Modern Methods of Diagnostics and Treatment of Neurodegenerative Diseases and Depression
Shusharina, N. N., Yukhnenko, D., Botman, S., Sapunov, V., Savinov, V., Kamyshov, G., Sayapin, D., & Voznyuk, I. A. (2023) · Diagnostics · doi:10.3390/diagnostics13030573 · Cited by 107
Dhiman, K., Gupta, V. B., Villemagne, V. L., Eratne, D., Graham, P. L., Fowler, C., Bourgeat, P., Li, Q., Collins, S., Bush, A. I., et al. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12005 · Cited by 93
Self-citationWu, X. G., Lv, Y., Du, Y., Chen, F., Reed, M. N., Hu, M. Y., Suppiramaniam, V. D., Tang, S., & Hong, H. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.06.018 · Cited by 100
A brief history of “Alzheimer disease”
Knopman, D. S., Petersen, R. C., & Jack, C. R. (2019) · Neurology · doi:10.1212/wnl.0000000000007583 · Cited by 104
Self-citationCurrent Concepts of Mixed Pathologies in Neurodegenerative Diseases
Forrest, S. L., & Kovács, G. G. (2022) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2022.34 · Cited by 104
Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome
Startin, C. M., Hamburg, S., Hithersay, R., Al‐Janabi, T., Mok, K. Y., Hardy, J., & Strydom, A. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.08.009 · Cited by 103
Wang, M., Jiang, J., Yan, Z., Alberts, I., Ge, J., Zhang, H., Zuo, C., Yu, J., Rominger, A., Shi, K., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04814-x · Cited by 98
Grill, J. D., Raman, R., Ernstrom, K. B., Sultzer, D. L., Burns, J. M., Donohue, M., Johnson, K. A., Aisen, P. S. S., Sperling, R. A., Karlawish, J. H., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2734 · Cited by 101
Self-citationBlood DNA methylation as a potential biomarker of dementia: A systematic review
Fransquet, P. D., Lacaze, P., Saffery, R., McNeil, J., Woods, R., & Ryan, J. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.10.002 · Cited by 96
Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease
Hunter, S., & Brayne, C. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.218 · Cited by 94
Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes
Gómez-Isla, T., & Frosch, M. P. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00642-9 · Cited by 96
Early functional network alterations in asymptomatic elders at risk for Alzheimer’s disease
Nakamura, A., Cuesta, P., Kato, T., Arahata, Y., Iwata, K., Yamagishi, M., Kuratsubo, I., Kato, K., Bundo, M., Diers, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06876-8 · Cited by 98
González‐Ortiz, F., Ferreira, P. C. L., González‐Escalante, A., Montoliu‐Gaya, L., Ortiz‐Romero, P., Kac, P. R., Turton, M., Kvartsberg, H., Ashton, N. J., Zetterberg, H., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13525 · Cited by 98
Self-citationEvolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment
Goldman, J. G., Holden, S. K., Litvan, I., McKeith, I. G., Stebbins, G. T., & Taylor, J. (2018) · Movement Disorders · doi:10.1002/mds.27323 · Cited by 93
Intranasal drug delivery for treatment of Alzheimer’s disease
Fonseca, L., Lopes, J. A., Vieira, J., Viegas, C., Oliveira, C. S., Hartmann, R. P., & Fonte, P. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00940-7 · Cited by 93
Kamondi, A., Grigg-Damberger, M. M., Löscher, W., Tanila, H., & Horvath, A. A. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00932-4 · Cited by 104
Brain aging patterns in a large and diverse cohort of 49,482 individuals
Yang, Z., Wen, J., Erus, G., Govindarajan, S. T., Melhem, R., Mamourian, E., Cui, Y., Srinivasan, D., Abdulkadir, A., Parmpi, P., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03144-x · Cited by 102
Self-citationKamila, P., Kar, K., Chowdhury, S., Chakraborty, P., Dutta, R., S, S., Singh S, A., & Prajapati, B. G. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.05.005 · Cited by 90
Kovács, G. G., Andreasson, U., Liman, V., Regelsberger, G., Lutz, M. I., Danics, K., Keller, É., Zetterberg, H., & Blennow, K. (2017) · European Journal of Neurology · doi:10.1111/ene.13389 · Cited by 93
Self-citationvan Maurik, I. S., Zwan, M. D., Tijms, B. M., Bouwman, F. H., Teunissen, C. E., Scheltens, P., Wattjes, M. P., Barkhof, F., Berkhof, J. H., van der Flier, W. M., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2712 · Cited by 91
Self-citationDissociable influences of APOE ε4 and polygenic risk of AD dementia on amyloid and cognition
Ge, T., Sabuncu, M. R., Smoller, J. W., Sperling, R. A., Mormino, E. C., & Initiative, A. D. N. (2018) · Neurology · doi:10.1212/wnl.0000000000005415 · Cited by 94
Self-citationSocial Engagement and Amyloid-β-Related Cognitive Decline in Cognitively Normal Older Adults
Biddle, K. D., Uquillas, F. D., Jacobs, H. I. L., Zide, B. S., Kirn, D. R., Rentz, D. M., Johnson, K. A., Sperling, R. A., & Donovan, N. J. (2019) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.05.005 · Cited by 95
Self-citationAmyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti–Amyloid-β Therapy
Agarwal, A., Gupta, V., Brahmbhatt, P., Desai, A., Vibhute, P., Joseph-Mathurin, N., & Bathla, G. (2023) · RadioGraphics · doi:10.1148/rg.230009 · Cited by 90
Gallego-Rudolf, J., Wiesman, A. I., Binette, A. P., Villeneuve, S., & Baillet, S. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01763-8 · Cited by 109
How early can we diagnose Alzheimer disease (and is it sufficient)?
Petersen, R. C. (2018) · Neurology · doi:10.1212/wnl.0000000000006088 · Cited by 94
Prevalence of Alzheimer's Disease and Parkinson's Disease in China: An Updated Systematical Analysis
Cui, L., Hou, N.-N., Wu, H., Zuo, X., Lian, Y.-Z., Zhang, C., Wang, Z., Zhang, X., & Zhu, J. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.603854 · Cited by 88
Wong-Guerra, M., Calfío, C., Maccioni, R. B., & Rojo, L. E. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1161850 · Cited by 97
de Vargas, D. M., Bastiani, M. A. D., Zimmer, E. R., & Klamt, F. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0394-7 · Cited by 91
Wolk, D. A., Sadowsky, C., Safirstein, B., Rinne, J. O., Duara, R., Perry, R. J., Agronin, M., Gamez, J., Shi, J., Ivanoiu, A., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0894 · Cited by 89
Clinical utility of FDG-PET for the clinical diagnosis in MCI
for the EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders, Arbizu, J., Festari, C., Altomare, D., Walker, Z., Bouwman, F. H., Rivolta, J., Orini, S., Barthel, H., Agosta, F., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4039-7 · Cited by 90
Self-citationGao, F., Lv, X., Dai, L., Wang, Q., Wang, P., Cheng, Z., Xie, Q., Ni, M., Wu, Y., Chai, X., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12700 · Cited by 91
Plasma p‐tau immunoassays in clinical research for Alzheimer's disease
Teunissen, C. E., Kolster, R., Triana‐Baltzer, G., Janelidze, S., Zetterberg, H., & Kolb, H. C. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14397 · Cited by 96
Cespón, J., Miniussi, C., & Pellicciari, M. C. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.03.001 · Cited by 93
Solomon, A., Stephen, R., Altomare, D., Carrera, E., Frisoni, G. B., Kulmala, J., Molinuevo, J. L., Nilsson, P. M., Ngandu, T., Ribaldi, F., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00875-8 · Cited by 86
Self-citationPuzo, C. J., Labriola, C., Sugarman, M. A., Tripodis, Y., Martin, B. M., Palmisano, J. N., Steinberg, E. G., Stein, T. D., Kowall, N. W., McKee, A. C., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0521-0 · Cited by 85
Marková, H., Andel, R., Štěpánková, H., Kopeček, M., Nikolai, T., Hort, J., Thomas-Antérion, C., & Vyhnálek, M. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160970 · Cited by 92
Understanding Epigenetics in the Neurodegeneration of Alzheimer’s Disease: SAMP8 Mouse Model
Griñán‐Ferré, C., Corpas, R., Puigoriol‐Illamola, D., Palomera‐Ávalos, V., Sanfeliu, C., & Pallàs, M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170664 · Cited by 86
Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
Vogt, A. S., Jennings, G. T., Mohsen, M. O., Vogel, M., & Bachmann, M. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043895 · Cited by 88
Optical coherence tomography angiography of the retina and choroid in systemic diseases
Chua, J., Tan, B., Wong, D. W. K., Garhöfer, G., Liew, X. W., Popa‐Cherecheanu, A., Chin, C. W. L., Miléa, D., Chen, C., & Schmetterer, L. F. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101292 · Cited by 98
Iulita, M. F., Millón, M. B. B., Pentz, R., Aguilar, L. F., Carmo, S. D., Allard, S. T. M., Michalski, B., Wilson, E. N., Ducatenzeiler, A., Bruno, M. A., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.08.019 · Cited by 87
A Systematic Review of Longitudinal Studies Which Measure Alzheimer’s Disease Biomarkers
Lawrence, E., Vegvari, C., Ower, A. K., Hadjichrysanthou, C., de Wolf, F., & Anderson, R. M. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170261 · Cited by 89
Duan, Y., Lu, L., Chen, J., Wu, C., Liang, J., Zheng, Y., Wu, J., Rong, P., & Tang, C. (2018) · BMC Geriatrics · doi:10.1186/s12877-018-0864-6 · Cited by 86
The Impact of Estradiol on Neurogenesis and Cognitive Functions in Alzheimer’s Disease
Negah, S. S., Hajali, V., Moradi, H. R., & Gorji, A. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00733-0 · Cited by 83
Dimache, A.-M., Șalaru, D. L., Sascău, R. A., & Stătescu, C. (2021) · Nutrients · doi:10.3390/nu13062118 · Cited by 87
Macdonald, I. R., Maxwell, S. P., Reid, G. A., Cash, M. K., DeBay, D. R., & Darvesh, S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170164 · Cited by 85
Complexity Measures for Quantifying Changes in Electroencephalogram in Alzheimer’s Disease
Al-Nuaimi, A. H. H., Jammeh, E., Sun, L., & Ifeachor, E. (2018) · Complexity · doi:10.1155/2018/8915079 · Cited by 82
Defining pre-symptomatic amyotrophic lateral sclerosis
Benatar, M. G., Turner, M. R., & Wuu, J. (2019) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2019.1587634 · Cited by 80
Eren, E., Hunt, J. F. V., Shardell, M. D., Chawla, S., Tran, J., Gu, J., Vogt, N. M., Johnson, S. C., Bendlin, B. B., & Kapogiannis, D. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12130 · Cited by 81
Ge, K., Li, Z., Wang, A., Bai, Z., Zhang, X., Zheng, X., Liu, Z., & Gao, F. (2023) · ACS Nano · doi:10.1021/acsnano.2c08499 · Cited by 83
Eye-tracking paradigms for the assessment of mild cognitive impairment: a systematic review
Wolf, A., Tripanpitak, K., Umeda, S., & Otake, M. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1197567 · Cited by 92
Metadata
- Authors
- Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., Broich, K., Cavedo, E., Crutch, S., Dartigues, J., Duyckaerts, C., Epelbaum, S., Frisoni, G. B., Gauthier, S., Genthon, R., Gouw, A. A., Habert, M., Holtzman, D. M., Kivipelto, M., Lista, S., Molinuevo, J., O'Bryant, S. E., Rabinovici, G. D., Rowe, C., Salloway, S., Schneider, L. S., Sperling, R., Teichmann, M., Carrillo, M. C., Cummings, J., Jack, C. R., & Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on “The Preclinical State of AD”; July 23, 2. W. D.
- Affiliations
- Sorbonne Université (FR)
- University of British Columbia (CA)
- Amsterdam Neuroscience (NL)
- University of Southern California (US)
- Université Toulouse III - Paul Sabatier (FR)
- Institut du Cerveau (FR)
- Centre National de la Recherche Scientifique (FR)
- Institute for Integrative and Experimental Genomics (DE)
- Sahlgrenska University Hospital (SE)
- Federal Institute for Drugs and Medical Devices (DE)
- Centro San Giovanni di Dio Fatebenefratelli (IT)
- UCL Queen Square Institute of Neurology (GB)
- Université de Bordeaux (FR)
- University of Geneva (CH)
- Douglas Mental Health University Institute (CA)
- Fondation pour la Recherche sur Alzheimer Hôpital Pitié‐Salpêtrière Paris France
- Washington University in St. Louis (US)
- Karolinska University Hospital (SE)
- AXA Research Fund (FR)
- Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain
- Center for Alzheimer's & Neurodegenerative Disease Research University of North Texas Health Science Center TX USA
- University of California, San Francisco (US)
- The University of Melbourne (AU)
- Brown University (US)
- Brigham and Women's Hospital (US)
- The Alzheimer's Association Division of Medical & Scientific Relations Chicago USA
- Cleveland Clinic (US)
- Department of Radiology Mayo Clinic Rochester MN USA
- Corresponding author
- Dubois, Bruno
- ORCID
- Dubois, Bruno
- Hampel, Harald
- Feldman, Howard H.
- Scheltens, Philip
- Andrieu, Sandrine
- Bakardjian, Hovagim
- Benali, Habib
- Bertram, Lars
- Blennow, Kaj
- Broich, Karl
- Cavedo, Enrica
- Crutch, Sebastian
- Dartigues, Jean‐François
- Duyckaerts, Charles
- Epelbaum, Stéphane
- Frisoni, Giovanni B.
- Gauthier, Serge
- Gouw, Alida A.
- Habert, Marie‐Odile
- Holtzman, David M.
- Kivipelto, Miia
- Lista, Simone
- Rabinovici, Gil D.
- Rowe, Christopher
- Salloway, Stephen
- Schneider, Lon S.
- Sperling, Reisa
- Teichmann, Marc
- Cummings, Jeffrey
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2016-03
- Volume
- 12
- Issue
- 3
- Pages
- 292-323
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC6417794
- OpenAlex
- W2309442902
- Cited by
- 1,925
- References
- 298
- Citations by year
- 2026: 115 · 2025: 176 · 2024: 244 · 2023: 245 · 2022: 247 · 2021: 244 · 2020: 176 · 2019: 157 · 2018: 161 · 2017: 112 · 2016: 47
- FWCI
- 22.78
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- AXA Research Fund
- National Institute on Aging
- Alzheimer's Association
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- preclinical Alzheimer's disease, Alzheimer's disease continuum
- MeSH terms
- Alzheimer Disease, Animals, Brain, Humans, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
